By Adriano Marchese

 

Koninklijke Philips NV said Thursday that a study of its InCourage system found positive results, with lower rates of hospitalization and antibiotic use in patients with chronic respiratory issues.

The Dutch medical-technology company said the peer-reviewed study of airway clearance use for bronchiectasis monitored 2,596 patients receiving high frequency chest wall oscillation therapy using the InCourage system for one year.

The study found that in the first year of use, the rate of hospitalization dropped 54.5%, self-reported ability to clear lungs improved to 76.6% from 13.9% and antibiotic use fell to 29.9% from 57.7%, the company said.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

July 23, 2020 09:31 ET (13:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Koninklijke Philips NV
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Koninklijke Philips NV